Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board
LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Dr. Marco Del Chiaro, a world recognized expert surgeon in pancreatic diseases, transplantation and robotic surgery has been appointed to the company’s Scientific Advisory Board.
Marco Del Chiaro, MD, PhD, FACS is presently an associate professor of surgery and Head of Pancreatic Surgery Unit at the Division of Surgery, Department of Clinical Science, Intervention and Technology at Karolinska Institute and senior consultant surgeon at Karolinska University Hospital.
Marco Del Chiaro received his medical degree from Pisa University, Italy, where he also completed his residency in general and transplant surgery. He received his PhD degree in new technologies for health from the same institution. Dr Del Chiaro is revisor of the European Pancreatic Club, member of the council of the International Association of Pancreatology and he is the founder and coordinator of the Italian Registry of Familial Pancreatic Cancer, of the Young Pancreatologist Platform in Europe and of the European Study Group on Cystic Tumors of the Pancreas.
“We are delighted that Dr. Marco Del Chiaro has agreed to join Immunovia’s Scientific Advisory Board. As a world leading surgeon expert on pancreatic diseases, he will bring invaluable experience and insights to our pancreatic cancer program,” said Mats Grahn, CEO, Immunovia.
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
About Pancreatic Cancer
Pancreatic Cancer is one of the most deadly and difficult to detect cancers, as the signs and symptoms are diffuse and similar to other diseases. There are more than 40,000 deaths and over 50,000 new cases diagnosed each year in the U.S. alone, and the five-year survival rate for pancreatic cancer is currently 4-6%. It is predicted to become the second leading cause of cancer death by 2020. However, because resection is more successful in stage I/II, can significantly improve pancreatic cancer patients’ 5-year survival rates from 4-6% to potentially 50-60%.